The European Commission (EC) has granted marketing authorization for Teva Pharmaceutical’s Cinqaero (reslizumab) in all European Union (EU) nations, Norway, Liechtenstein, and Iceland. The therapy treats inadequately controlled asthma in adult and ... Read more